On January 9, 2014, the Health Resources and Services Administration (HRSA) posted an update on its current and anticipated 340B drug pricing program (340B) program integrity efforts.1 The update includes a discussion of HRSA’s recent enhanced compliance oversight activities, including final results of HRSA’s audits of 340B covered entities. HRSA also provides an update on the status of its long-awaited 340B regulations. Based on this update from HRSA, it appears 2014 will be another active year with respect to HRSA’s 340B program integrity efforts and may result in critical clarification and/or changes to the 340B program.